Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins

Virology

Volumn 371, Issue 2, 2008, Pages 394-404

  Sundstrom, Magnus ^a   Chatterji, Udayan ^a   Schaffer, Lana ^a   de Rozières, Sohela ^a   Elder, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Affymetrix; FIV; Ingenuity; Microarray; OrfA; Proteasome; Spliceosome; Splicing factors; Ubiquitination

Indexed keywords

GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2; PROTEASOME; PROTEIN ORFA; TRANSACTIVATOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VPR PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CLONE; FELINE IMMUNODEFICIENCY VIRUS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC COMPLEMENTATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROCESSING; REVERSE TRANSCRIPTION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; UBIQUITINATION; VIRUS REPLICATION;

ANIMALS; CATS; CELL LINE; GENE EXPRESSION REGULATION; GENOME, VIRAL; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; MICE; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OPEN READING FRAMES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; T-LYMPHOCYTES; UBIQUITIN; VIRUS REPLICATION;

FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 38649087320     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.09.039     Document Type: Article

References (66)

1. Apcher G.S., Heink S., Zantopf D., Kloetzel P.M., Schmid H.P., Mayer R.J., and Kruger E. Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits. FEBS Lett. 553 1-2 (2003) 200-204
2. Breitling R., Armengaud P., Amtmann A., and Herzyk P. Rank Products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 573 1-3 (2004) 83-92
3. Caputi M., Mayeda A., Krainer A.R., and Zahler A.M. hnRNP A/B proteins are required for inhibition of HIV-1 pre-mRNA splicing. EMBO J. 18 14 (1999) 4060-4067
4. Chatterji U., de Parseval A., and Elder J.H. Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators. J. Virol. 76 19 (2002) 9624-9634
5. Chiu Y.L., Coronel E., Ho C.K., Shuman S., and Rana T.M. HIV-1 Tat protein interacts with mammalian capping enzyme and stimulates capping of TAR RNA. J. Biol. Chem. 276 16 (2001) 12959-12966
6. Darzynkiewicz Z., and Juan G. Current Protocols in Cytometry (1997), John Wiley & Sons, New York
7. de Parseval A., and Elder J.H. Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity. J. Virol. 73 1 (1999) 608-617
8. de Parseval A., and Elder J.H. Binding of recombinant feline immunodeficiency virus surface glycoprotein to feline cells: role of CXCR4, cell-surface heparans, and an unidentified non-CXCR4 receptor. J. Virol. 75 10 (2001) 4528-4539
9. de Parseval A., Lerner D.L., Borrow P., Willett B.J., and Elder J.H. Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding. J. Virol. 71 8 (1997) 5742-5749
10. Domsic J.K., Wang Y., Mayeda A., Krainer A.R., and Stoltzfus C.M. Human immunodeficiency virus type 1 hnRNP A/B-dependent exonic splicing silencer ESSV antagonizes binding of U2AF65 to viral polypyrimidine tracts. Mol. Cell. Biol. 23 23 (2003) 8762-8772
11. Fleckner J., Zhang M., Valcarcel J., and Green M.R. U2AF65 recruits a novel human DEAD box protein required for the U2 snRNP-branchpoint interaction. Genes Dev. 11 14 (1997) 1864-1872
12. Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., Bonaccorsi A., Marastoni M., Micheletti F., Cafaro A., Rimessi P., Caputo A., and Ensoli B. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J. Immunol. 173 6 (2004) 3838-3843
13. Gemeniano M.C., Sawai E.T., Leutenegger C.M., and Sparger E.E. Feline immunodeficiency virus ORF-A is required for virus particle formation and virus infectivity. J. Virol. 77(16) (2003) 8819-8830
14. Gemeniano M.C., Sawai E.T., and Sparger E.E. Feline immunodeficiency virus Orf-A localizes to the nucleus and induces cell cycle arrest. Virology 325 2 (2004) 167-174
15. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 2 (2002) 373-428
16. Graveley B.R. Sorting out the complexity of SR protein functions. RNA 6 9 (2000) 1197-1211
17. Hashizume C., Kuramitsu M., Zhang X., Kurosawa T., Kamata M., and Aida Y. Human immunodeficiency virus type 1 Vpr interacts with spliceosomal protein SAP145 to mediate cellular pre-mRNA splicing inhibition. Microbes Infect. 9 4 (2007) 490-497
18. Huang X., Seifert U., Salzmann U., Henklein P., Preissner R., Henke W., Sijts A.J., Kloetzel P.M., and Dubiel W. The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing. J. Mol. Biol. 323 4 (2002) 771-782
19. Jacquenet S., Mereau A., Bilodeau P.S., Damier L., Stoltzfus C.M., and Branlant C. A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H. J. Biol. Chem. 276 44 (2001) 40464-40475
20. Johnson W.E., Li C., and Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8 1 (2007) 118-127
21. Kammler S., Otte M., Hauber I., Kjems J., Hauber J., and Schaal H. The strength of the HIV-1 3′ splice sites affects Rev function. Retrovirology 3 (2006) 89
22. Kim Y.K., Bourgeois C.F., Pearson R., Tyagi M., West M.J., Wong J., Wu S.Y., Chiang C.M., and Karn J. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J. 25 15 (2006) 3596-3604
23. Kloetzel P.M., and Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16 1 (2004) 76-81
24. Lerner D.L., Grant C.K., de Parseval A., and Elder J.H. FIV infection of IL-2-dependent and-independent feline lymphocyte lines: host cells range distinctions and specific cytokine upregulation. Vet. Immunol. Immunopathol. 65 2-4 (1998) 277-297
25. Luhrmann R., Kastner B., and Bach M. Structure of spliceosomal snRNPs and their role in pre-mRNA splicing. Biochim. Biophys. Acta 1087 3 (1990) 265-292
26. McLaren M., Asai K., and Cochrane A. A novel function for Sam68: enhancement of HIV-1 RNA 3′ end processing. RNA 10 7 (2004) 1119-1129
27. Modem S., Badri K.R., Holland T.C., and Reddy T.R. Sam68 is absolutely required for Rev function and HIV-1 production. Nucleic Acids Res. 33 3 (2005) 873-879
28. Naghavi M.H., Nowak P., Andersson J., Sonnerborg A., Yang H., Tracey K.J., and Vahlne A. Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner. Virology 314 1 (2003) 179-189
29. Nekhai S., Zhou M., Fernandez A., Lane W.S., Lamb N.J., Brady J., and Kumar A. HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem. J. 364 Pt 3 (2002) 649-657
30. Nowak P., Barqasho B., Treutiger C.J., Harris H.E., Tracey K.J., Andersson J., and Sonnerborg A. HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages. Cytokine 34 1-2 (2006) 17-23
31. O'Neil L.L., Burkhard M.J., Diehl L.J., and Hoover E.A. Vertical transmission of feline immunodeficiency virus. Semin. Vet. Med. Surg. (Small Anim.) 10 4 (1995) 266-278
32. O'Neil L.L., Burkhard M.J., and Hoover E.A. Frequent perinatal transmission of feline immunodeficiency virus by chronically infected cats. J. Virol. 70 5 (1996) 2894-2901
33. Obert L.A., and Hoover E.A. Relationship of lymphoid lesions to disease course in mucosal feline immunodeficiency virus type C infection. Vet. Pathol. 37 5 (2000) 386-401
34. Olmsted R.A., Hirsch V.M., Purcell R.H., and Johnson P.R. Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc. Natl. Acad. Sci. U. S. A. 86 20 (1989) 8088-8092
35. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., Pendergast A.M., Bronson R., Aster J.C., Scott M.L., and Baltimore D. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92 10 (1998) 3780-3792
36. Pedersen N.C. Immunogenicity and efficacy of a commercial feline leukemia virus vaccine. J. Vet. Intern. Med. 7 1 (1993) 34-39
37. Pedersen N.C., Ho E.W., Brown M.L., and Yamamoto J.K. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235 4790 (1987) 790-793
38. Phillips T.R., Talbott R.L., Lamont C., Muir S., Lovelace K., and Elder J.H. Comparison of two host cell range variants of feline immunodeficiency virus. J. Virol. 64 10 (1990) 4605-4613
39. Pistello M., Moscardini M., Mazzetti P., Bonci F., Zaccaro L., Isola P., Freer G., Specter S., Matteucci D., and Bendinelli M. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 298 1 (2002) 84-95
40. Pocernich C.B., Boyd-Kimball D., Poon H.F., Thongboonkerd V., Lynn B.C., Klein J.B., Calebrese V., Nath A., and Butterfield D.A. Proteomics analysis of human astrocytes expressing the HIV protein Tat. Brain Res. Mol. Brain Res. 133 2 (2005) 307-316
41. Poon B., Chang M.A., and Chen I.S. Vpr is required for efficient nef expression from unintegrated human immunodeficiency virus type 1 DNA. J. Virol. 81 19 (2007) 10515-10523
42. Purcell D.F., and Martin M.A. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J. Virol. 67 11 (1993) 6365-6378
43. Qi M., and Aiken C. Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism. J. Virol. 81 3 (2007) 1534-1536
44. Radmacher M.D., McShane L.M., and Simon R. A paradigm for class prediction using gene expression profiles. J. Comput. Biol. 9 3 (2002) 505-511
45. Remoli A.L., Marsili G., Perrotti E., Gallerani E., Ilari R., Nappi F., Cafaro A., Ensoli B., Gavioli R., and Battistini A. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem. J. 396 2 (2006) 371-380
46. Rogers A.B., and Hoover E.A. Maternal-fetal feline immunodeficiency virus transmission: timing and tissue tropisms. J. Infect. Dis. 178 4 (1998) 960-967
47. Ropers D., Ayadi L., Gattoni R., Jacquenet S., Damier L., Branlant C., and Stevenin J. Differential effects of the SR proteins 9G8, SC35, ASF/SF2, and SRp40 on the utilization of the A1 to A5 splicing sites of HIV-1 RNA. J. Biol. Chem. 279 29 (2004) 29963-29973
48. Rozen S., and Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132 (2000) 365-386
49. Ryo A., Suzuki Y., Arai M., Kondoh N., Wakatsuki T., Hada A., Shuda M., Tanaka K., Sato C., Yamamoto M., and Yamamoto N. Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cells. AIDS Res. Hum. Retrovir. 16 10 (2000) 995-1005
50. Seeger M., Ferrell K., Frank R., and Dubiel W. HIV-1 tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation. J. Biol. Chem. 272 13 (1997) 8145-8148
51. Sillekens P.T., Habets W.J., Beijer R.P., and van Venrooij W.J. cDNA cloning of the human U1 snRNA-associated A protein: extensive homology between U1 and U2 snRNP-specific proteins. EMBO J. 6 12 (1987) 3841-3848
52. Sillekens P.T., Beijer R.P., Habets W.J., and van Verooij W.J. Molecular cloning of the cDNA for the human U2 snRNA-specific A′ protein. Nucleic Acids Res. 17 5 (1989) 1893-1906
53. Sparger E.E., Shacklett B.L., Renshaw-Gegg L., Barry P.A., Pedersen N.C., Elder J.H., and Luciw P.A. Regulation of gene expression directed by the long terminal repeat of the feline immunodeficiency virus. Virology 187 1 (1992) 165-177
54. Stoltzfus C.M., and Madsen J.M. Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing. Curr. HIV Res. 4 1 (2006) 43-55
55. Talbott R.L., Sparger E.E., Lovelace K.M., Fitch W.M., Pedersen N.C., Luciw P.A., and Elder J.H. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 86 15 (1989) 5743-5747
56. Tange T.O., Damgaard C.K., Guth S., Valcarcel J., and Kjems J. The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element. Embo J. 20 20 (2001) 5748-5758
57. Terada Y., and Yasuda Y. Human immunodeficiency virus type 1 Vpr induces G2 checkpoint activation by interacting with the splicing factor SAP145. Mol. Cell. Biol. 26 21 (2006) 8149-8158
58. van 't Wout A.B., Lehrman G.K., Mikheeva S.A., O'Keeffe G.C., Katze M.G., Bumgarner R.E., Geiss G.K., and Mullins J.I. Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4(+)-T-cell lines. J. Virol. 77 2 (2003) 1392-1402
59. Viscidi R.P., Mayur K., Lederman H.M., and Frankel A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 246 4937 (1989) 1606-1608
60. Wang J., Xiao S.H., and Manley J.L. Genetic analysis of the SR protein ASF/SF2: interchangeability of RS domains and negative control of splicing. Genes Dev. 12 14 (1998) 2222-2233
61. Wang H., Ward M.F., Fan X.G., Sama A.E., and Li W. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol. 19 1 (2006) 3-9
62. Waters A.K., De Parseval A.P., Lerner D.L., Neil J.C., Thompson F.J., and Elder J.H. Influence of ORF2 on host cell tropism of feline immunodeficiency virus. Virology 215 1 (1996) 10-16
63. Wei B.L., Denton P.W., O'Neill E., Luo T., Foster J.L., and Garcia J.V. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J. Virol. 79 9 (2005) 5705-5712
64. Wen X., Duus K.M., Friedrich T.D., and de Noronha C.M. The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J. Biol. Chem. 282 37 (2007) 27046-27057
65. Wu X., Anderson J.L., Campbell E.M., Joseph A.M., and Hope T.J. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. U. S. A. 103 19 (2006) 7465-7470
66. Zahler A.M., Damgaard C.K., Kjems J., and Caputi M. SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing. J. Biol. Chem. 279 11 (2004) 10077-10084